Advances in Novel Biomaterial-Based Strategies for Spinal Cord Injury Treatment.

IF 4.5 2区医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL

Molecular Pharmaceutics Pub Date : 2024-09-05 DOI:10.1021/acs.molpharmaceut.3c01104

Nannan Zhang, Jiaqi Hu, Wenlong Liu, Wenjun Cai, Yun Xu, Xiaojuan Wang, Shun Li, Bin Ru

{"title":"Advances in Novel Biomaterial-Based Strategies for Spinal Cord Injury Treatment.","authors":"Nannan Zhang, Jiaqi Hu, Wenlong Liu, Wenjun Cai, Yun Xu, Xiaojuan Wang, Shun Li, Bin Ru","doi":"10.1021/acs.molpharmaceut.3c01104","DOIUrl":null,"url":null,"abstract":"<p><p>Spinal cord injury (SCI) is a highly disabling neurological disorder. Its pathological process comprises an initial acute injury phase (primary injury) and a secondary injury phase (subsequent chronic injury). Although surgical, drug, and cell therapies have made some progress in treating SCI, there is no exact therapeutic strategy for treating SCI and promoting nerve regeneration due to the complexity of the pathological SCI process. The development of novel drug delivery systems to treat SCI is expected to significantly impact the individualized treatment of SCI due to its unique and excellent properties, such as active targeting and controlled release. In this review, we first describe the pathological progression of the SCI response, including primary and secondary injuries. Next, we provide a concise overview of newly developed nanoplatforms and their potential application in regulating and treating different pathological processes of SCI. Then, we introduce the existing potential problems and future clinical application perspectives of biomedical engineering-based therapies for SCI.</p>","PeriodicalId":52,"journal":{"name":"Molecular Pharmaceutics","volume":null,"pages":null},"PeriodicalIF":4.5000,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Pharmaceutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1021/acs.molpharmaceut.3c01104","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Spinal cord injury (SCI) is a highly disabling neurological disorder. Its pathological process comprises an initial acute injury phase (primary injury) and a secondary injury phase (subsequent chronic injury). Although surgical, drug, and cell therapies have made some progress in treating SCI, there is no exact therapeutic strategy for treating SCI and promoting nerve regeneration due to the complexity of the pathological SCI process. The development of novel drug delivery systems to treat SCI is expected to significantly impact the individualized treatment of SCI due to its unique and excellent properties, such as active targeting and controlled release. In this review, we first describe the pathological progression of the SCI response, including primary and secondary injuries. Next, we provide a concise overview of newly developed nanoplatforms and their potential application in regulating and treating different pathological processes of SCI. Then, we introduce the existing potential problems and future clinical application perspectives of biomedical engineering-based therapies for SCI.

Abstract Image

查看原文本刊更多论文

基于新型生物材料的脊髓损伤治疗策略的进展。

脊髓损伤（SCI）是一种高度致残的神经系统疾病。其病理过程包括最初的急性损伤阶段（原发性损伤）和继发性损伤阶段（后续慢性损伤）。虽然手术、药物和细胞疗法在治疗 SCI 方面取得了一些进展，但由于 SCI 病理过程的复杂性，目前还没有治疗 SCI 和促进神经再生的确切治疗策略。治疗 SCI 的新型给药系统具有主动靶向和控释等独特的优良特性，有望对 SCI 的个体化治疗产生重大影响。在本综述中，我们首先描述了 SCI 反应的病理进展，包括原发性和继发性损伤。接着，我们简要概述了新开发的纳米平台及其在调节和治疗 SCI 不同病理过程中的潜在应用。然后，我们介绍了基于生物医学工程的 SCI 治疗方法的现有潜在问题和未来临床应用前景。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Molecular Pharmaceutics 医学-药学

CiteScore

8.00

自引率

6.10%

发文量

391

审稿时长

2 months

期刊介绍： Molecular Pharmaceutics publishes the results of original research that contributes significantly to the molecular mechanistic understanding of drug delivery and drug delivery systems. The journal encourages contributions describing research at the interface of drug discovery and drug development. Scientific areas within the scope of the journal include physical and pharmaceutical chemistry, biochemistry and biophysics, molecular and cellular biology, and polymer and materials science as they relate to drug and drug delivery system efficacy. Mechanistic Drug Delivery and Drug Targeting research on modulating activity and efficacy of a drug or drug product is within the scope of Molecular Pharmaceutics. Theoretical and experimental peer-reviewed research articles, communications, reviews, and perspectives are welcomed.